been carried out initially. Treatment cycle consisted of 28 days on and 14 days off therapy respectively (Standard schedule = Sta-S). A pharmacokinetic assessment of sunitinib concentrations was carried out. Based on low-trough sunitinib concentrations (Cmin) observed during the first two cycles, the third treatment cycle started at 37.5 mg/day during 14 days and was increased to 50 mg/day the following 14 days (Table 1) . Grade I thrombocytopenia, grade 2 asthenia and mucositis occurred during the third and the fourth week of the cycle. One decided to modulate sunitinib administration into a different schedule previously published, with 2 weeks on at 50 mg/day followed by 1 week off [1] . It allowed the same dose intensity with more frequent off treatment phases. The patient received four modified schedules (Mod-S) with only grade 1 mucositis and asthenia. The pharmacokinetics assessment showed an optimal exposure (Table 1) . Scanner carried out after 3 and 6 months of treatment confirmed a partial response.
pharmacokinetics assessments
Blood samples for the determination of plasma trough concentrations (Cmin) were collected just before the daily administration of sunitinib. An area under the concentration -time curve (AUC (0-24 h) ) was realized 18 days after the beginning of the first cycle of treatment (C1-D18). Sunitinib concentrations were determined using ultra performance liquid chromatography coupled with tandem mass spectrometer [2] .
The AUC (0-24 h) realized at the steady state during the first cycle (C1-D18) was 0.866 hÁlg/ml which is consistent with previously published data [3] . Results of sunitinib Cmin determination for Sta-S and Mod-S are summarized in Table 1 . Using the modified schedule, trough plasma concentrations above 50 ng/ml were achieved at D7 and D14, with very low Cmin at D1.
discussion
Two small studies (24 and 19 patients) suggest that pharmacokinetics in subjects with severe renal impairment appear similar to those with normal renal function and that patients with severe renal impairment can be safely treated with sunitinib [4, 5] .
Previous data obtained among patients with renal insufficiency undergoing hemodialysis suggest that sunitinib administered at a dose of 50 mg/day for 4 weeks is well tolerated and lead to plasma concentrations and pharmacokinetic parameters similar to those reported in patients with normal renal function [4, [6] [7] [8] . In addition, sunitinib seems not to be dialyzable and therefore administration may be anytime before or after the hemodialysis session [6] .
Doses of 50 mg/day led to plasmatic Cmin ranging from 50 to 100 ng/ml [3]. Phase I study has shown that potentially active target plasma concentrations need to be ‡50 ng/ml. Most patients with dose-limiting toxicity had combined (sunitinib plus SU012662) trough plasma concentrations ‡100 ng/mL [3] . A meta-analysis (443 patients with pharmacokinetic data) indicated that increased exposure to sunitinib is associated with improved clinical outcomes (longer time to tumor progression, longer overall survival, greater chance of antitumor response) [9] . It has been published before that both AUC and Cmin increase dose proportionately in a range of dose included between 50 and 100 mg [3] . Therefore, our patient sunitinib concentration was monitored by one initial evaluation of sunitinib AUC and then by regular evaluations of its Cmin. It was more convenient for him with the advantages of an outpatient monitoring and less blood tests. With modified schedule, we achieved optimal trough plasma concentrations. Our case supports the need for drug pharmacological monitoring to warrant optimal exposure to sunitinib in patients with abnormal conditions.
A. for Cmin £ 10 ng/ml; for 10 < Cmin £ 50 ng/ml; for 50 < Cmin £ 100 ng/ml. s, standard schedule ; m, modified schedule. 
